Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Zeekpudsa, Ponsilp ^a,b   Kukongviriyapan, Veerapol ^a,b   Senggunprai, Laddawan ^a,b   Sripa, Banchob ^a,b   Prawan, Auemduan ^a,b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

5 fluorouracil (5 FU); Cholangiocarcinoma (CCA); Doxorubicin (Doxo); Gemcitabine (Gem); NAD(P)H quinone oxidoreductase 1 (NQO1); p53

Indexed keywords

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BILE DUCT NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84892704442     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-11     Document Type: Article

References (30)

1. Cholangiocarcinoma. Lazaridis KN, Gores GJ, Gastroenterology 2005 128 1655 1667 10.1053/j.gastro.2005.03.040 15887157 (Pubitemid 40692558)
2. Cholangiocarcinoma. Patel T, Nat Clin Pract Gastroenterol Hepatol 2006 3 33 42 10.1038/ncpgasthep0389 16397610 (Pubitemid 43102075)
3. Cholangiocarcinoma: lessons from Thailand. Sripa B, Pairojkul C, Curr Opin Gastroenterol 2008 24 349 356 10.1097/MOG.0b013e3282fbf9b3 18408464 (Pubitemid 351535894)
4. Cancer incidence in Thailand, 1995-1997. Sriplung H, Sontipong S, Martin N, Wiangnon S, Vootiprux V, Cheirsilpa A, Kanchanabat C, Khuhaprema T, Asian Pac J Cancer Prev 2005 6 276 281 16235986
5. Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case-controlled study. Kurathong S, Lerdverasirikul P, Wongpaitoon V, Pramoolsinsap C, Kanjanapitak A, Varavithya W, Phuapradit P, Bunyaratvej S, Upatham ES, Brockelman WY, Gastroenterology 1985 89 151 156 2989071 (Pubitemid 15057924)
6. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S, Cancer Res 1978 38 4634 4639 214229 (Pubitemid 9065143)
7. Cholangiocarcinoma. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD, Lancet 2005 366 1303 1314 10.1016/S0140-6736(05)67530-7 16214602 (Pubitemid 41416587)
8. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Fodale V, Pierobon M, Liotta L, Petricoin E, Cancer J 2011 17 89 95 10.1097/PPO.0b013e318212dd3d 21427552
9. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S, Cancer Res 2003 63 2649 2657 12750293 (Pubitemid 36605209)
10. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Siegel D, Ross D, Free Radic Biol Med 2000 29 246 253 10.1016/S0891-5849(00)00310-5 11035253
11. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M, Cancer Epidemiol Biomarkers Prev 2006 15 979 987 10.1158/1055-9965.EPI-05-0899 16702380 (Pubitemid 43823527)
12. Dicumarol inhibition of NADPH: quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cullen JJ, Hinkhouse MM, Grady M, Gaut AW, Liu J, Zhang YP, Weydert CJ, Domann FE, Oberley LW, Cancer Res 2003 63 5513 5520 14500388 (Pubitemid 37139871)
13. Regulation of genes encoding NAD(P)H: quinone oxidoreductases. Jaiswal AK, Free Radic Biol Med 2000 29 254 262 10.1016/S0891-5849(00)00306-3 11035254
14. NAD(P)H: quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Long DJ 2nd, Waikel RL, Wang XJ, Perlaky L, Roop DR, Jaiswal AK, Cancer Res 2000 60 5913 5915 11085502
15. NAD(P)H: quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D, Chem Biol Interact 2000 129 77 97 10.1016/S0009-2797(00) 00199-X 11154736 (Pubitemid 32061055)
16. Inflammatory cytokines suppress NAD(P)H:quinone oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells. Prawan A, Buranrat B, Kukongviriyapan U, Sripa B, Kukongviriyapan V, J Cancer Res Clin Oncol 2009 135 515 522 10.1007/s00432-008-0483-2 18820947
17. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H, Int J Oncol 2002 21 1119 1124 12370763
18. High levels of expression of the NAD(P)H: quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Cresteil T, Jaiswal AK, Biochem Pharmacol 1991 42 1021 1027 10.1016/0006-2952(91)90284-C 1651729
19. Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation. Matsui Y, Watanabe J, Ding S, Nishizawa K, Kajita Y, Ichioka K, Saito R, Kobayashi T, Ogawa O, Nishiyama H, BJU Int 2010 105 558 564 10.1111/j.1464-410X.2009.08732.x 19583730
20. Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines. Watanabe J, Nishiyama H, Matsui Y, Ito M, Kawanishi H, Kamoto T, Ogawa O, Oncogene 2006 25 2500 2508 10.1038/sj.onc.1209162 16518417
21. NQO1 expression correlates with cholangiocarcinoma prognosis. Buranrat B, Chau-In S, Prawan A, Puapairoj A, Zeekpudsa P, Kukongviriyapan V, Asian Pac J Cancer Prev 2012 13 Suppl 131 136
22. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. Buranrat B, Prawan A, Kukongviriyapan U, Kongpetch S, Kukongviriyapan V, World J Gastroenterol 2010 16 2362 2370 10.3748/wjg.v16.i19.2362 20480521
23. Quinone reductase inhibitors block SAPK/JNK and NFkappaB pathways and potentiate apoptosis. Cross JV, Deak JC, Rich EA, Qian Y, Lewis M, Parrott LA, Mochida K, Gustafson D, Vande Pol S, Templeton DJ, J Biol Chem 1999 274 31150 31154 10.1074/jbc.274.44.31150 10531305 (Pubitemid 29508465)
24. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Asher G, Lotem J, Cohen B, Sachs L, Shaul Y, Proc Natl Acad Sci USA 2001 98 1188 1193 10.1073/pnas.98.3.1188 11158615 (Pubitemid 32121208)
25. Specificity protein 1-dependent p53-mediated suppression of human manganese superoxide dismutase gene expression. Dhar SK, Xu Y, Chen Y, St Clair DK, J Biol Chem 2006 281 21698 21709 10.1074/jbc.M601083200 16740634 (Pubitemid 44181873)
26. BCL-2 family: regulators of cell death. Chao DT, Korsmeyer SJ, Annu Rev Immunol 1998 16 395 419 10.1146/annurev.immunol.16.1.395 9597135 (Pubitemid 28183370)
27. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T, Green DR, Proc Natl Acad Sci USA 2008 105 20327 20332 10.1073/pnas.0808036105 19074266
28. Dissecting p53-dependent apoptosis. Chipuk JE, Green DR, Cell Death Differ 2006 13 994 1002 10.1038/sj.cdd.4401908 16543937
29. Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathway. Zheng C, Jia W, Tang Y, Zhao H, Jiang Y, Sun S, J Exp Clin Cancer Res 2012 31 84 10.1186/1756-9966-31-84 23034174
30. Ratio disruption of the 133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. Nutthasirikul N, Limpaiboon T, Leelayuwat C, Patrakitkomjorn S, Jearanaikoon P, Int J Oncol 2013 42 1181 1188 23404110